Riccardo Pofi1,2, Chona Feliciano3, Emilia Sbardella2, Nicola Argese4, Conor P Woods5, Ashley B Grossman1, Bahram Jafar-Mohammadi1, Helena Gleeson3, Andrea Lenzi2, Andrea M Isidori2, Jeremy W Tomlinson1. 1. Department of Endocrinology, Oxford Centre for Diabetes, Endocrinology, and Metabolism and National Institute for Health Research Oxford Biomedical Research Centre, Churchill Hospital, University of Oxford, Oxford, United Kingdom. 2. Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy. 3. Centre for Endocrinology, Diabetes, and Metabolism, Queen Elizabeth Hospital, Birmingham, United Kingdom. 4. Department of Endocrinology, S.S. Annunziata Hospital, Taranto, Italy. 5. Department of Endocrinology, Naas General Hospital, Kildare and Tallaght Hospital, Dublin, Ireland.
Abstract
Context: The 250-μg short Synacthen (corticotropin) test (SST) is the most commonly used tool to assess hypothalamo-pituitary-adrenal (HPA) axis function. There are many potentially reversible causes of adrenal insufficiency (AI), but no data to guide clinicians as to the frequency of repeat testing or likelihood of HPA axis recovery. Objective: To use the SST results to predict adrenal recovery. Design: A retrospective analysis of 1912 SSTs data. Patients: Seven hundred seventy-six patients with reversible causes of AI were identified who had at least two SSTs performed. A subgroup analysis was performed on individuals previously treated with suppressive doses of glucocorticoids (n = 110). Main Outcome Measures: Recovery of HPA axis function. Results: SST 30-minute cortisol levels above or below 350 nmol/L (12.7 μg/dL) best predicted HPA axis recovery [area under the curve (AUC) receiver operating curve (ROC) = 0.85; median recovery time: 334 vs 1368 days, P = 8.5 × 10-13]: 99% of patients with a 30-minute cortisol >350 nmol/L recovered adrenal function within 4 years, compared with 49% in those with cortisol levels <350 nmol/L. In the subgroup analysis, delta cortisol (30-minute-basal) best predicted the recovery (AUC ROC = 0.77; median recovery time: 262 vs 974 days, P = 7.0 × 10-6). No patient with a delta cortisol <100 nmol (3.6 μg/dL) and a subsequent 1-year random cortisol <200 nmol/L (7.3 μg/dL) recovered HPA axis function. Conclusions: Cortisol levels across an SST can be used to predict recovery of AI and may guide the frequency of repeat testing and inform both clinicians and patients as to the likelihood of restoration of HPA axis function.
Context: The 250-μg short Synacthen (corticotropin) test (SST) is the most commonly used tool to assess hypothalamo-pituitary-adrenal (HPA) axis function. There are many potentially reversible causes of adrenal insufficiency (AI), but no data to guide clinicians as to the frequency of repeat testing or likelihood of HPA axis recovery. Objective: To use the SST results to predict adrenal recovery. Design: A retrospective analysis of 1912 SSTs data. Patients: Seven hundred seventy-six patients with reversible causes of AI were identified who had at least two SSTs performed. A subgroup analysis was performed on individuals previously treated with suppressive doses of glucocorticoids (n = 110). Main Outcome Measures: Recovery of HPA axis function. Results: SST 30-minute cortisol levels above or below 350 nmol/L (12.7 μg/dL) best predicted HPA axis recovery [area under the curve (AUC) receiver operating curve (ROC) = 0.85; median recovery time: 334 vs 1368 days, P = 8.5 × 10-13]: 99% of patients with a 30-minute cortisol >350 nmol/L recovered adrenal function within 4 years, compared with 49% in those with cortisol levels <350 nmol/L. In the subgroup analysis, delta cortisol (30-minute-basal) best predicted the recovery (AUC ROC = 0.77; median recovery time: 262 vs 974 days, P = 7.0 × 10-6). No patient with a delta cortisol <100 nmol (3.6 μg/dL) and a subsequent 1-year random cortisol <200 nmol/L (7.3 μg/dL) recovered HPA axis function. Conclusions: Cortisol levels across an SST can be used to predict recovery of AI and may guide the frequency of repeat testing and inform both clinicians and patients as to the likelihood of restoration of HPA axis function.
Authors: A M Isidori; G Arnaldi; M Boscaro; A Falorni; C Giordano; R Giordano; R Pivonello; C Pozza; E Sbardella; C Simeoli; C Scaroni; A Lenzi Journal: J Endocrinol Invest Date: 2019-11-26 Impact factor: 4.256
Authors: T Feola; R Sa Pirchio; G Puliani; R Pofi; M Crocco; V Sada; F Sesti; F Verdecchia; D Gianfrilli; M Appetecchia; N Di Iorgi; M L Jaffrain-Rea; R Pivonello; A M Isidori; A B Grossman; E Sbardella Journal: J Endocrinol Invest Date: 2022-08-24 Impact factor: 5.467
Authors: F Bioletto; A M Berton; E Varaldo; D Cuboni; C Bona; M Parasiliti-Caprino; N Prencipe; E Ghigo; S Grottoli; M Maccario; V Gasco Journal: J Endocrinol Invest Date: 2022-09-26 Impact factor: 5.467
Authors: Sophie A Clarke; Maria Phylactou; Bijal Patel; Edouard G Mills; Beatrice Muzi; Chioma Izzi-Engbeaya; Sirazum Choudhury; Bernard Khoo; Karim Meeran; Alexander N Comninos; Ali Abbara; Tricia Tan; Waljit S Dhillo Journal: J Clin Endocrinol Metab Date: 2021-07-13 Impact factor: 5.958
Authors: Teumzghi F Mebrahtu; Ann W Morgan; Adam Keeley; Paul D Baxter; Paul M Stewart; Mar Pujades-Rodriguez Journal: J Clin Endocrinol Metab Date: 2019-04-22 Impact factor: 5.958